Coronavirus Vaccine Candidate AZD1222 Resumes Phase 3 Study

AstraZeneca announced on September 12, 2020, that late-stage clinical trials for the coronavirus vaccine candidate, AZD1222, have resumed in the United Kingdom (UK) following confirmation by the Medicines Health Regulatory Authority that it was safe to do so.

AstraZeneca's press statement indicated the University of Oxford, as the trial sponsor, cannot disclose further medical information. And the trial investigators and participants will be updated with the relevant information.

Furthermore, this news will be disclosed on global clinical registries, according to the clinical trial and regulatory standards. While phase 3 trials can now resume in the U.K., the status of trials around the world remains unclear, as of 11:00 EST.